Recurrent Multiple Myeloma

Darzalex® Approved for Additional Indications in Multiple Myeloma (11-29-2016)

The United States Food and Drug Administration (FDA) has approved Darzalex® (daratumumab) for the treatment of multiple myeloma among patients who have received at least one prior therapy. The new FDA indication also requires that daratumumab be used... Continue Reading

Darzalex™ Effective in Heavily Pre-Treated Multiple Myeloma (07-7-2016)

The targeted agent Darzalex (daratumumab) produces long-lasting anti-cancer responses among patients with multiple myeloma that has stopped responding to several prior therapies. These results were recently published in the journal Blood. Multiple myeloma... Continue Reading

Aplidin® Improves Progression-Free Survival in Multiple Myeloma (04-21-2016)

The addition of the investigative agent Aplidin® (plitidepsin) to dexamethasone appears to significantly reduce the risk of cancer progression or death compared to dexamethasone alone among patients with multiple myeloma that has progressed following... Continue Reading

Combo Therapy of Kyprolis plus Dexamethasone Approved for Recurrent Multiple Myeloma (01-26-2016)

The United States Food and Drug Administration (FDA) recently approved a new treatment combination consisting of Kyprolis (carfilzomib) plus dexamethasone for patients with relapsed or refractory multiple myeloma. Multiple myeloma is a type of blood cancer... Continue Reading

Leukemia and Lymphoma Society Summarizes Major Advances in Treatment of Blood Cancers Presented at American Society of Hematology Meetings (12-31-2015)

For the more than one million Americans living with or in remission from a blood cancer, there is more hope than ever for new treatments and even cures—not someday, but today. Clinical findings presented at the 57th American Society of Hematology (ASH)... Continue Reading

FDA Approves Empliciti for Multiple Myeloma (12-7-2015)

The United States Food and Drug Administration (FDA) has approved Empliciti (elotuzumab) for the treatment of patients with multiple myeloma who have received prior therapies. The indication specifies that Empliciti is to be used in combination with lenalidomide... Continue Reading

Ninlaro® Approved for Multiple Myeloma (11-23-2015)

The United States Food and Drug Administration (FDA) has granted approval to Ninlaro® (ixazomib) for the treatment of multiple myeloma. This marks the third drug approved this year for the treatment of multiple myeloma. The approval specifies that Ninlaro... Continue Reading

FDA Approves Darzalex Providing a New Treatment for Patients with Multiple Myeloma (11-17-2015)

Today the U.S. Food and Drug Administration granted accelerated approval for Darzalex (daratumumab) to treat patients with multiple myeloma. Darzalex is the first monoclonal antibody approved for treating multiple myeloma. Darzalex appears to be effective... Continue Reading

Daratumumab Effective in Multiple Myeloma (09-17-2015)

The targeted agent, daratumumab, which is still in clinical trials, appears to be effective in patients with multiple myeloma that has stopped responding to standard therapies. These results were recently published in the New England Journal of Medicine. Multiple... Continue Reading

Immunotherapy Benefits Patients with Drug-Resistant Multiple Myeloma (09-2-2015)

In its first clinical trial, a breakthrough antibody therapy produced at least partial remissions in a third of patients with multiple myeloma who had exhausted multiple prior treatments, investigators at Dana-Farber Cancer Institute and other organizations... Continue Reading

Next Page »